Selective scoring of drug effects in multicellular co-culture systems
Authors:
Preprint
Abstract
Multicellular co-culture screening reveals compound effects that depend on cell-cell interactions. Standard dose-response metrics fail to resolve effects that arise either from target-effector cell interactions or from non-specific toxic effects. Here, we developed Co-culture Efficacy Score (CES), a robust computational framework that enables systematic identification of compounds that selectively modulate cellular interactions in multicellular assays. CES framework supports both therapeutic scoring that penalizes direct effector cell toxicity, as well as a mechanistic discovery that estimates immunomodulatory effects by adjusting for effector cell responses. When screening 527 compounds across 10 hematological cancer models co-cultured with natural killer (NK) cells, CES distinguished co-culture-specific immunomodulatory effects from NK cell toxicity and cancer cell inhibitory responses, recovering systematic enhancer and inhibitory patterns. We further assessed CES robustness using higher-resolution validation screens and demonstrated its applicability to identify selective compounds in anti-CD19 CAR T-cell and antiviral host-pathogen screens. To facilitate its broad use, we implemented CES as an interactive web-application for quantitative analysis of compound responses in co-culture assays, providing a widely applicable scoring framework for cancer immunotherapy, antiviral screening and drug discovery.Keywords
Funding Information
- EU Horizon Europe research and innovation Programme (EP PerMed (GA N° 101137129))
This publication has 57 references indexed in Scilit:
- Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancersImmunity, 2023
- Functional precision cancer medicine: drug sensitivity screening enabled by cell culture modelsTrends in Pharmacological Sciences, 2022
- Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinationsCancer Cell, 2021
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018
- Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profilingLeukemia, 2017
- Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLLeukemia, 2016
- A Landscape of Pharmacogenomic Interactions in CancerCell, 2016
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint BlockadeImmunity, 2016
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012